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Abstract
Raman microspectroscopy is gaining popularity for the analysis of time-dependent biological processes such as
drug uptake and cellular response. It is a label-free technique which acquires signals from a large variety of
components, including cell biomolecules and exogenous compounds such as drugs and nanoparticles, and is
commonly employed for in vitro analysis of cells and cell populations with no labelling or staining required. By
monitoring the changes to the Raman spectra of the cell as a result of a perturbing agent (e.g. inoculation of a
drug or toxic agent), one can study the associated changes in cell biochemistry involved in both, the disruption
and the subsequent cellular response. The main challenge is that the Raman spectra should be data mined in order
to extract the information corresponding to the different actors involved on the process. Here, we study the
application of multivariate curve resolution-alternating least squares (MCR-ALS) for extracting kinetic and
biochemical information of time-dependent cellular processes. The technique allows the elucidation of the
concentration profiles as well as the pure spectra of the components involved. Initially, we used Ordinary
Differential Equations (ODE) to simulate drug uptake and 2 responses, which were employed to simulate
perturbations to experimental control spectra, creating a dataset containing 36 simulated Raman spectra. Four
different scenarios governing the drug exposure-response were evaluated: an undetectable disruption (e.g.
radiation), a detectable disruption (e.g. a drug) and disruption with a signal significantly larger than the biological
changes induced (e.g. a resonant drug), as well as simultaneous and asynchronous responses. Subsequently, data
acquired from the exposure of a pulmonary adenocarcinoma cell line (A549) to Doxorubicin was analysed. The
results indicate that MCR-ALS can independently identify and isolate both the spectra of the drug and the cell
1

responses under the different scenarios. The predicted concentrations map out the drug uptake and cellular
response curves. The technique shows great potential to investigate non-linear kinetics and modes of action.
Advantages and limitations of the technique are discussed, providing guidelines for future analysis strategies.
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Introduction
The EU and US (EU Directive-2010/63/EU and US Public Law 106-545, 2010, 106th Congress) have put in place
legislation for the protection of animals used for scientific research and fostered research on the development of
alternative methods for toxicity and safety testing to address legislative requirements. In this context, Raman
microspectroscopy is a promising technique for the in vitro investigation of cellular drug uptake and modes of
action.[1] The lateral resolution of confocal Raman microspectroscopy, typically in the hundreds of nanometre to
micrometre range, allows spatial characterisation of organelles in cells[2]. Besides, as water is a weak Raman
scatterer, the method is ideal for use in the living environment of cells[3]. By monitoring the spectra of the
different cellular regions (e.g. cytoplasm, nucleus and nucleolus) after drug inoculation, a large amount of
molecular information of the cell can be obtained, including the presence of the drug as well as metabolic changes
induced. [4,5] Raman spectroscopy has been shown to be very efficient in monitoring the effect of the drug over
time, which is essential to understand the drug mode (i.e. molecular targets of the drug) and mechanism of action
(i.e. phenotypic changes induced by the drug).[6] By investigating the evolution of the Raman bands of the drug,
the drug metabolites and the rest of the components, one can establish the composition ratio of the drug and the
molecules which are affected by the drug. [7–10]

Different biomolecules (i.e. proteins, carbohydrates, nucleic acids and lipids), as well as drugs, can present highly
overlapped Raman signatures and thus, the spectra can be used for extracting information about the drug uptake
and the phenotypic responses induced by the drug. However, Raman data sets are complex and should be data
mined using multivariate methods to extract biologically meaningful information.[11]
Although in most of the cases the cell functional responses as well as drug metabolism and uptake are changing
in a non-linear fashion with time, linear algorithms, such as Partial Least Squares Regression (PLSR),[12] are
commonly used to model these effects.[13–15] This implies building a model in which the predicted Y is the time
value, and then studying the contribution of the different variables (either negative or positive) to the linear model,
as manifest in the regression vector. As an alternative, orthogonal partial least squares regression (OPLSR) is an
3

extension of PLS which applies an orthogonal correction filter to extract spectral variations important to the
prediction from the variations orthogonal to the time.[16] Although the performance of OPLSR models is
generally largely equivalent to that provided by PLSR, OPLSR models gain in terms of interpretability of the
variables, all the variance associated with Y being represented in the first latent variable (LV). Other methods to
investigate these systems include two-dimensional[17] correlation analysis and Principal Component
Analysis[18].
Two main problems are anticipated when using PLSR based techniques for the investigation of the temporal
evolution of responses associated with drug modes and mechanisms of action. Firstly, while the Raman signal is
linear with the concentration of Raman active biochemical compounds, both drug uptake and cellular responses
follow diverse non-linear kinetic patterns [19]. Secondly, the regression vector cannot decompose the spectral
variations which occur at different rates, being unable to differentiate spectral changes associated with the drug
from variations associated with the subsequent cellular response. This restricts the use of PLSR to different time
ranges in order to capture different linear regions of the drug uptake and response.[20]
Multivariate Curve Resolution - Alternating Least Squares (MCR-ALS) is used for resolving multiple component
responses of unresolved mixtures, resolving the bilinear model

by an alternative least squares iterative

optimisation.[21] The bilinear model is defined as:
𝑫 = 𝑪 𝑺𝑻 + E (1)

(Equation 1)

In which D (i × j) is the matrix of spectral data of i samples and j variables, and C (i × n) is the concentration
matrix containing the concentrations of the N components of the system for each spectrum. ST (n × j) is the
transpose of the spectra of the pure components and E (i x j) is the residual matrix. When a temporal evolution is
considered, MCR-ALS extracts: i) the concentration C matrix of the components over i time points and ii) the
pure spectrum of each component on the matrix S. The former matrix is useful for studying the kinetics of the
process and the latter to assign the bimolecular aetiology of each component. This technique is extremely useful
in monitoring changes in complex and potentially non-linear temporal evolutions of multicomponent systems
such as biological ones. It is also based on a bilinear model of Raman intensities and concentration of components
4

in a sample. However, MCR-ALS decomposes the spectral data matrix for a selected number of pure component
spectra and concentration vectors. The concentration profiles can follow non-linear dependences with time, as
defined by multiple kinetic equations.
In this work, using simulated and real data, we evaluate the use of MCR-ALS to decompose the Raman spectra
of cells upon inoculation of a drug, to establish a kinetic model of the drug uptake, and cellular responses. First,
we used Ordinary differential Equations (ODE) to simulate drug uptake and 2 subsequent response curves, which
were added as time dependent perturbations to control cellular spectra, creating a dataset containing 36 simulated
Raman spectra. Different scenarios were considered: The first represented the inclusion of an external
perturbation which does not have a detectable Raman signal, simulating for example the effect of radiation or a
drug or toxic with concentration below the limit of detection. The second scenario was simulated considering a
drug or toxic with a specific Raman signature, with an intensity comparable to the cell component bands. The last
scenario simulated the inoculation of a resonant drug with a Raman signal which is significantly stronger than the
cell Raman signatures, potentially resonantly enhanced. Regarding the phenotypic changes induced by the
presence of the drug, both simultaneous and asynchronous responses were analysed. MCR-ALS was applied
considering different constraints, including non-negativity in the concentrations and spectra, and the results
obtained were compared to those obtained by OPLSR. The results indicate that MCR-ALS can isolate and capture
both the spectra of the drug and the cell responses under the different scenarios, in comparison with OPLSR,
which only provided information about the mean trends of the spectral changes with time. Finally, a real dataset
was studied, derived from the in vitro subcellular analysis of the time dependent uptake and localisation of the
drug doxorubicin (DOX) in human lung cancer cells (A549)[20]. The predicted concentrations map out the drug
uptake and cellular response curves. The technique shows great potential to investigate non-linear kinetics and
modes of action.

5

Materials and Methods
Here, we provide a summary of the materials and methods used for the experimental data. Further information
can be accessed in the original publications[17,20].
Cell culture and inoculation
A549 cells were cultured in DMEM-F12 with 10% fetal bovine serum (FBS) and Calu-1 cells in RPMI with 10%
FBS, both at 37°C in a humidified atmosphere containing 5% CO2 and cells were split every two days to maintain
~60% confluency.
Cells (~ 1x 104/window) were seeded and incubated on CaF2 windows (Crystan Ltd, UK) for 24 h for both control
and exposure to DOX. The medium was then removed and samples were rinsed twice with sterile PBS and
covered with DOX at the corresponding IC50 inhibitory concentration, adjusted to the cell number[20] . After each
incubation period, 2, 6, 12, 24, 48 and 72 h, cells were washed twice with sterile PBS and fixed in formalin (4%,
15 min).[22]

Raman Spectroscopy
A Horiba Jobin-Yvon LabRAM HR800 spectrometer with a 785 nm, 300 mW diode laser as source, Peltier cooled
16-bit CCD, 300 lines/mm grating and 100 μm confocal hole, was used for this work. Spectra were acquired in
the range from 400 cm-1 to 1800 cm-1 using a x100 objective (LCPlanN, Olympus), in dry conditions, for 30s two
times, from three cell locations: cytoplasm, nucleus and nucleolus, visible under white light illumination. A final
data set of 30 spectra per cell location for each time point, 2, 6, 12, 24, 48 and 72 h was produced after DOX
exposure and for control cells, for each cell line, amounting to a total of over 210 cells per cell line, corresponding
to a total data set of 1260 spectra. For the purpose of this study, data from the nucleolus only were considered.

Data Simulation

6

Experimental control spectra were derived from the study of Farhane et al.[20] , measured as described above,
and the 30 nucleolar spectra averaged. Based on the results of the PLSR analysis of the original study, simulated
early (Response 1) and late (Response 2) spectral response profiles were generated in the Horiba Labspec 5
software, as described in Byrne et al.[17] The temporal evolution of the respective contributions of the simulated
responses were derived according to the rate equations described in the “Results Section”. Simulated datasets
were created by adding weighted sums of the responses to the control spectra using the Matlab 2019a platform
(Mathworks, Natick, MA, USA).
Data Analysis
Data Treatment and data analysis is available at the Zenodo repository (10.5281/zenodo.3339285). Data analysis
was performed using MATLAB 2019a from Mathworks (Natick, MA, USA). MCR-ALS was performed using
the Graphical user interface available at https://mcrals.wordpress.com/.[23,24] Non negativity constrains were used
for both spectra and concentrations. Considering the absence of maxima and minima in the concentration profiles,
a unimodality constraint was also applied to the concentration. Pure spectra were normalised using the total sum
(i.e. Each spectrum was divided by the total sum of the spectra). This step ensured that all the pure spectra
computed were in a similar range. A maximum of 50 iterations were considered, employing a tolerance sigma
value of 0.1. The initial estimations of the concentrations were obtained using those column profiles from the
original data matrix which were numerically most different. The number of components tested varied from 2 to
3, depending on the Single Value Decomposition analysis performed prior to the MCR-ALS. Two kinds of MCRALS models were considered: without equality constraints and with equality constraints involving one
component. In the latter case, the pure spectrum was forced to be the initial spectrum (InC) and the concentration
was fixed to 1 for all the time points. Firstly, MCR-ALS was used without any equality constraint. If the model
provided results with rotational ambiguity, the constraint was introduced.
OPLSR models were calculated using the PLS_Toolbox 8.6 from Eigenvector Res. Inc. (Manson, WA, USA).
Standard Normal Variate (SNV) and mean centring was used for spectral pre-processing. Model complexity (i.e.
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number of LVs) was selected as the smallest number for which a decrease in the RMSECV between consecutive
LVs was less than 3%.
Results
Simulation of spectral responses of cells under different scenarios
Simulations were based on previous works by Farhane et al.[20] and Byrne et al[17], which identified spectral
responses of A549 cells to the inoculation of DOX over time, in the subcellular regions of nucleolus, nucleus and
cytoplasm. Considering only the example of the nucleolus, the studies indicated that the interaction of DOX
induced two perturbations to the spectra. The first response (Mode of action) was synchronous with the drug
uptake and was caused by the binding of the drug to the RNA and DNA, resulting in a decrease of phosphate
bands, including the 785 cm-1 band (associated with RNA and DNA O-P-O stretching), the 1095 cm−1 band
(assigned to the DNA PO2− symmetric stretching), and the 1683 cm−1 (protein Amide I). The second response
(Mechanism of action) was subsequent to the drug uptake and was related to the phenotypic response of the cell
to the drug, including an increased intensity of the RNA-sugar phosphate band at 1047 cm-1, amide III band at
1271 cm-1 and CH2 deformation band at 1444 cm-1. Figure 1 shows the simulated spectral responses (Response 1
and Response 2) caused by the drug, along with the spectrum of the drug itself.

8

Figure 1. (Colour) Spectral profiles of the initial component (IC) simulated responses and experimental spectra
of DOX (Top). Simulated and real datasets employed on the study. Dataset I: Undetectable disruption, subtractive
Response 1 and additive Response 2. Dataset II: Detectable disruption, additive Response 1 and additive
Response 2. Dataset III: Enhanced response (e.g. DOX), subtractive Response 1 and additive Response 2.
The effects of drug uptake after inoculation on a cell, described by the intensity of Responses 1 and 2, can be
simulated considering ordinary differential equations[17]. 𝑁𝑏 , the number of DOX molecules bound to DNA
and𝑁𝑟 , the intensity of the subsequent cellular response as a function of time can be expressed as:
𝑑𝑁𝑏
𝑑𝑡
𝑑𝑁𝑟
𝑑𝑡

= (𝑁𝑟𝑒𝑐𝑝 − 𝑁𝑏 )𝐾𝑢𝑝 𝐷

(2)

= (𝑁𝑟𝑒𝑠𝑝 − 𝑁𝑟 )𝐾𝑟𝑒𝑠𝑝 𝑁𝑏

(3)

Where 𝐾𝑢𝑝 and 𝐾𝑟𝑒𝑠𝑝 describe the drug uptake and response rates, respectively (2.5 × 10−4 and 2.5 × 10−6 h-1 in
this study), D is the drug dose, 𝑁𝑟𝑒𝑐𝑝 is the number of receptors in the nucleolus and 𝑁𝑟𝑒𝑠𝑝 is a parameter to limit
9

the number of responses. To simulate the measured cellular responses, the spectral responses, weighted according
to their temporal evolution, can be added to a measured, control dataset.
In this study, the use of MCR-ALS to different scenarios in which the phenotype of a cell is disrupted by an
external agent was evaluated in simulated spectral data sets using the profiles calculated from equations (1) and
(2) (see Figure 2a), and considering extrinsic perturbations with and without identifiable Raman spectral
signatures as well as additive and subtractive spectral contributions.
Dataset I. Undetectable perturbation, subtractive response 1 and additive response 2.
This dataset simulates the effect of a perturbing factor which does not have its own a characteristic Raman
spectrum, as is the case, for example, for ionising or non-ionising radiation, or a drug or toxicant which does not
have a strong Raman signature at the dose applied [25]. The presence of this perturbation provokes a synchronous
alteration of the cellular composition (i.e. Response 1, e.g. DNA damage) that triggers a subsequent molecular
response of the cell (Response 2). Such a response can be simulated according to equation 4:
S1 (t) = IC - SR1IR1(t) + SR2IR2(t) + N (4)
Where IC is the initial component (i.e. Raman spectrum of the cell without the drug), SR1 and SR2 are the simulated
spectra of the Responses 1 and 2, respectively and IR1 (t) and IR2 (t) are the simulated intensity profiles of
Responses 1 and 2, respectively. N is Gaussian noise, computed as the 0.1 % of the length (maximum of the
dataset minus minimum of the dataset) of the spectra ).
The simulated data set is depicted in Figure 1, showing the decrease of RNA band intensities associated with the
simulated Response 1 and the increase of the intensity of protein bands due to the simulated subsequent Response
2. Figures 2a and b show the intensity and spectral profiles of the responses used for the simulation. The spectral
profiles obtained from the MCR-ALS analysis (Figure 2d) were highly correlated with the simulated spectra.
MCR-ALS components 1 and 2 were assigned to the simulated responses 2 and 1, respectively, and the Pearson
correlation coefficients between the reference and predicted spectra were higher than 0.99. The variations of the
concentration of these components as a function of time are depicted in Figure 2c. The concentration of MCR10

ALS component 2 showed a monotonic decrease, reaching a plateau after 20 h, in agreement with the simulated
concentration of Response 1. In contrast, MCR-ALS component 1 showed an increase in concentration, highly
correlated with the simulated concentration of Response 2. Thus, MCR-ALS was able to extract both the spectral
responses and the time dependant profiles of both responses. Results from the analysis of the simulated data set
by OPLSR are shown in Figures 2e and 2f. The first OPLSR loading, which represents the spectral variance
associated with time, showed negative bands at 785, 811, 1099 and 1670 cm-1 (i.e. Response 1) and positive bands
at 1047, 1275 and 1436 cm-1 (i.e. Response 2). Cross validated predicted time values showed a significant
correlation between the simulated spectra and the time (see Figure 2e). However, a basic assumption of PLSR is
that the association between the changes in the spectra and the response (i.e. time) is linear. The simulated data
set included non-linear responses and so, the generalisation performance of PLSR is limited and the model may
not be adequate as shown by the non-uniform distribution of the residuals of the y predicted values. In contrast,
MCR-ALS provides a more accurate description of the non-linear relationship between the two components with
time. Asynchronous subtractive and additive responses were represented as decreasing and increasing signatures
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Figure 2. (Colour) MCR-ALS and OPLSR analysis of Dataset I (Undetectable disruption, substractive Response
1 and addytive Response 2). Simulated time evolution (a) and simulated spectral signatures (b) employed on the
creation of Dataset I, simulating the spectral signatures of the disruption (Response 1) and subsequent cellular
response (Response 2). Concentration (c) and spectral (d) profiles determined by the MCR-ALS. Actual time
values versus predicted (by cross validation) time values (e) and first loading vector of the OPLSR (f).
Concentration profiles on a) and c) have been normalised to the range [0 1]. Spectra in b) and d) have been
shifted on the y axis for clarity.
Dataset II. Detectable disruption, additive response 1 and additive response 2.
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Dataset II simulates the effect of a Raman active perturbation factor, such as a drug or particle with a concentration
above the limit of detection. Its subcellular interaction provokes a simultaneous Response 1, which represents the
binding of the molecule or particle to the molecules of the cell and a subsequent phenotypic response of the cell
(Response 2). Dataset II was simulated according to equation 5:
S2(t)= IC + SDrugIDrug(t) + SR1IR1(t) + SR2IR2(t) + N (5)
in which SDrug and IDrug are the spectra and concentration profile of the perturbing agent, in this case the drug
spectrum and its dynamic uptake, respectively. Here, we assumed a negligible concentration of free drug
compared to the bound drug, and that the drug uptake and Response 1 occur simultaneously. Also, in this case
we also changed the sign of Response 1 to explore the use of MCR-ALS under additive conditions (i.e. the
perturbative interaction resulted in an increase in the contribution of constituent cellular components). A visual
inspection of the spectra of dataset II (Figure 1) revealed spectral variations associated with Responses 1 and 2,
as well as characteristic drug bands.
The accuracy of the MCR-ALS decomposition is demonstrated by the high degree of correlation observed
between the simulated spectral profiles (Figure 3d) and the spectra of the components obtained by MCR-ALS
(Figure 3b). Raman bands of the second MCR-ALS component were assigned to Response 2 and Raman bands
of the first MCR-ALS component are consistent with a combination of the spectra of the drug and Response 1.
As expected, MCR-ALS was not able to resolve the simulated drug internalisation and cellular response as two
independent components, because both processes are synchronous. If they had different kinetics, it would have
been possible to use the known DOX spectra as a pure spectrum to help resolve the system. Nonetheless, the
MCR-ALS estimated concentration profiles obtained, depicted in Figure 3c, are highly correlated with the
intensity profiles employed for the simulation (Figure 3a). In this case, the profile corresponding to the first MCRALS component, which represented the simultaneous uptake of drug and cell response increased over time.
Analysis by OPLSR (see Figure 3e and f) revealed again the lack of the linearity of the spectra and time. Although
the first loading appropriately indicated an increase of DOX, Response 1 and Response 2 bands, MCR-ALS
provided a more accurate description of the different non-linear spectral variations in the dataset over time.
13

Figure 3. (Colour) MCR-ALS and OPLSR analysis of Dataset II (Detectable disruption, additive Response 1 and
additive Response 2). Simulated time evolution (a) and simulated spectral signatures (b) employed on the creation
of Dataset II, simulating the spectral signatures of the disruption (e.g. a drug) the bonding of the disruption
(Response 1) and subsequent cellular responses (Response 2). Concentration (c) and spectral (d) profiles
determined by MCR-ALS. Actual time values versus cross validated predicted time values (e) and first loading
vector of the OPLSR (f). Concentration profiles on a) and c) have been normalised to the range [0 1]. Spectra on
b) and d) have been shifted on the y axis for clarity.
Dataset III. Resonant Drug, subtractive response 1 and additive response 2.
Data III simulates specifically the in vitro inoculation of A549 cells with DOX. In this case, the perturbing effect
is a resonant drug and therefore its signal is comparable or significantly more intense than the signal associated

14

with the drug bonding (Response 1) and subsequent cellular metabolic reaction (Response 2). The representative,
Dataset III can be simulated according to:
S3(t)= IC + F SDrugIDrug(t) - SR1IR1(t) + SR2IR2(t) + N (6)
where F is a factor which increases the signal of the drug relatively to the signal of Response 1 and Response 2.
In this study F=8 was selected to match the values observed in the real dataset. Here, Response 1 was negative,
again to simulate the experimentally observed spectral signature of the drug bonding to RNA/DNA in the
nucleolus of the cell.
Three components were considered for the MCR-ALS analysis of this dataset, the first (i.e. component 3) being
the initial cellular control spectrum, which was time independent. Spectral bands of MCR-ALS component 2
(Figure 4b) were seen to be highly correlated with Response 2 (R2= 0.9935), although the spectrum was slightly
contaminated with bands from DOX, such as those at 1620 and 420 cm-1 and control cellular components such as
the Phenylalanine band at 1005 cm-1. The concentration profile of this component also followed that of Response
2 (Figure 4b). A visual inspection of the first MCR-ALS component revealed a high correlation with the DOX
spectrum (R2= 0.9963). Bands of Response 1 should also be present in this component, as they were simulated to
occur simultaneously. However, in contrast to Dataset II, in this case they should produce a negative contribution,
as in the case of Dataset I, for which the concentration profile indicated a decrease of the component. In the
specific scenario considered here, Component 2 should represent the increase of DOX bands and the simultaneous
decrease of Response 1 bands.
For dataset III, the concentration profile indicated a signal increase, similar to the simulated DOX uptake (see
Figure 4c). A close inspection of the spectra of first MCR-ALS component confirms the presence of bands with
a negative contribution at the Response 1 positions (insets below Figure 4d). Bands at 780 and 810 cm-1 were
flattened to the 0 value and bands at 1095 and 1685 cm-1 were found as negative shoulders of DOX bands. In
summary, Component 1 was a combination of a large contribution of the DOX spectrum minus a small
contribution of Response 1, correctly reproducing the information introduced in the simulation. From these
observations, it can be established that, in the case of a resonant drug, spectral signatures of the binding can be
15

masked by the large contribution of the drug, and that subtractive contributions will be represented as nodes in
the spectra. For comparison, the first loading vector of the OPLSR (Figure 4f) shows a combination of the three
sources of variation, dominated by the DOX bands, but also reveals small positive contributions of Response 2
and negative contributions of Response 1.

Figure 4. (Colour) MCR-ALS and OPLSR analysis of Dataset III (Detectable disruption, substractive Response
1 and additive Response 2). Simulated time evolution (a) and simulated spectral signatures (b) employed on the
creation of Dataset III, simulating the spectral signatures of the perturbation (e.g. a resonant drug) the bonding
of the drug (Response 1) and subsequent cellular responses (Response 2). Concentration (c) and spectral (d)
profiles determined by MCR-ALS. Actual time values versus predicted (by cross validation) time values (e) and
first loading vector of the OPLSR (f). Insets represent enlargement of the Component 2 spectral bands.
Concentration profiles on a) and c) have been normalised to the range [0 1]. Spectra on d) and b) have been
shifted on the y axis for clarity.
16

Experimental DOX Dataset
The experimental DOX dataset, previously described by Farhane et al.[18], was analysed using MCR-ALS and
OPLSR under the conditions described on the “Data Analysis” section. Figure 1 depicts the Raman dataset, which
shows similarities with Dataset III. For MCR-ALS, two components were used, as a third component provided
ambiguous results (see Electronic Suppslementary Material, SM1). The pure spectrum of MCR-ALS Component
2 (Figure 5d, blue) shows typical bands of the original cell, whereas the spectra of MCR-ALS Component 1
(green) shows signatures of DOX bands and decreasing bands of DNA at 782, 812 and 1680 cm-1. The temporal
evolution of the spectral profile (Figure 5a) indicates an increase of these bands, evidencing an increase of DOX
content and a decrease of DNA bands, which reaches a plateau after 16 h. This indicates that the real data follows
the simulated Response 1 of Dataset III. The OPLSR component loading (Figure 5d) also shows similar bands,
but it does not provide any kinetic information about the spectral evolution over time.
The ambiguity found when three components were employed confirms that the secondary cellular response,
expected to be similar to the simulated Response 2, was not identified in the real dataset. Nevertheless, it has to
be noted that the real dataset included only spectra collected at 7 time points, and this limited temporal resolution
hampered the resolution of complex cellular signatures. In order to study this, a further simulation experiment
with the Dataset III was performed in which MCR-ALS models from simulated data with different levels of noise
and number of time points were simulated. Figure 6 shows the similarity between the Response 2 spectral
signature and the MCR-ALS component calculated as the correlation coefficient, over different temporal
resolutions and noise levels. Results showed that, regardless the noise level, the quality of the resolved
concentration and spectral profiles improves with the number of time points.
In summary, the results indicate that MCR-ALS outperforms the OPLSR method in extracting kinetic information
as well as spectral markers of the different processes involved. On the other hand, in a recent study using the same
experimental data and simulation approach, the use of a two dimensional correlation analysis [17] method was
also able to determine that bands associated with Response 1 and Response 2 are asynchronous (i.e. they occurred
at different rates). It did it also for the real dataset, while in this study MCR-ALS was not able to detect the
17

Response 2, probably because the poor spatial resolution of the experimental data. However, compared to 2D
correlation, MCR-ALS was able to provide the concentration profiles over time, which are extremely useful for
the

study

of

the

kinetics

involved

on

the

drug

uptake

and

cellular

response.

Figure 5. (Colour) MCR-ALS and OPLSR analysis of the Real Dataset (A549 cells exposed to DOX). Reference
spectra of DOX (b) Concentration (a) and spectral (d) profiles determined by the MCR-ALS. Actual time values
versus predicted by CV time values (c) and first loading vector of the OPLSR (e). Spectra on b) and d) have been
shifted on the y axis for clarity.
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Figure 6. (Colour) Correlation coefficient of the spectral signature of Response 2 and the pure spectra extracted
by the MCR-ALS for datasets simulated using different amount of noise and temporal resolution.

Conclusions
Results indicated that MCR-ALS is a usefully method for investigating the temporal evolution of drug uptake and
cellular responses in cells in vitro. It outperforms OPLSR, as it provides kinetic information from different
components that can evolve according to different non-linear time profiles. Dataset I indicated that additive and
subtractive perturbations of the constituent cellular components can be identified in the concentration profiles and
pure spectra profiles. Dataset II showed that simultaneous changes in molecules appear integrated as a single
component, the use of molecular information (e.g. prior knowledge about the location of drug bands) being
necessary to differentiate contributions of different species. Dataset III indicated that, if a component represents
both, additive and subtractive contributions, the spectrum calculated by MCR-ALS will contain positive bands
and nodes respectively.
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MCR-ALS applied to real data from DOX inoculations in A549 cells extracted a component representing the drug
uptake as well as the binding to DNA and RNA molecules. The dataset was limited in terms of temporal
resolution, which hampered the extraction of the subsequent, longer term cellular responses. In summary, the
application of MCR-ALS to decompose time series of Raman spectra after drug inoculation extracted significant
information about changes on cell composition induced by the presence of the drug. This could be applied in the
investigation of drug kinetics and modes of action and could be regarded as a revolutionary technique in
preclinical screening to improving drug effectivity and investigate drug resistance.
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